Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010

• Published in: Vaccine Vol. 31; no. 14; pp. 1819 - 1829
• Main Authors: Breugelmans, J.G, Lewis, R.F, Agbenu, E, Veit, O, Jackson, D, Domingo, C, Böthe, M, Perea, W, Niedrig, M, Gessner, B.D, Yactayo, S
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 03.04.2013; Elsevier; Elsevier Limited
• Subjects: Adult; Adverse event; Adverse event following immunization; Africa; Aged; Allergy and Immunology; Applied microbiology; Arboviroses; Biological and medical sciences; Child, Preschool; committees; Data processing; Disease prevention; Drug-Related Side Effects and Adverse Reactions; Encephalitis; Epidemiology; Fatalities; Female; Fever; Fundamental and applied biological sciences. Psychology; Genomes; Human viral diseases; Humans; hypersensitivity; Immunization; Infant; Infectious diseases; Laboratories; Male; Mass Vaccination - adverse effects; Medical sciences; Microbiology; Middle Aged; people; Pharmacovigilance; physiological transport; Surveillance; Tropical viral diseases; Unified database; Urine; vaccination; Vaccine safety; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vector-borne diseases; Viral diseases; Yellow fever; Yellow Fever - prevention & control; Yellow Fever Initiative; Yellow fever vaccine; Yellow Fever Vaccine - administration & dosage; Yellow Fever Vaccine - adverse effects; Yellow Fever Vaccine - immunology; Yellow fever vaccine associated neurologic disease; Yellow fever vaccine associated viscerotropic disease; Yellow fever vaccine safety; Yellow fever virus; Young Adult; Benin; Liberia; Cameroon; Guinea; Mali; Senegal; Sierra Leone; Africa; Burkina Faso; Yellow fever vaccine safety; yellow fever; yellow fever vaccine-associated viscerotropic disease; IFA; PV; acute disseminated encephalomyelitis; Unified database; Vaccine safety; adverse event following immunization; pharmacovigilance; YF; YFIC; ADEM; RT-PCR; CSF; yellow fever vaccine; yellow fever vaccine-associated neurologic disease; YFI; WHO; World Health Organization; immunofluorescent antibody; YEL-AND; Robert Koch Institut; YFV; Adverse event; NEC; YEL-AVD; Yellow fever vaccine associated neurologic disease; RKI; national expert committee; Yellow Fever Investment Case; cerebrospinal fluid; enzyme-linked immunosorbent assay; reverse transcription polymerase chain reaction; AEFI; Yellow Fever Initiative; Yellow fever vaccine associated viscerotropic disease; ELISA; Adverse event following immunization; Yellow fever; Yellow fever vaccine; Immunization; Yellow fever vaccine associated neurologic; disease; Toxicity; Vaccination; Vaccine; Yellow fever vaccine associated; viscerotropic disease; Infection; Viral disease; Arbovirus disease; Database
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2013.01.054

Highlights ► From 2007 to 2010, African countries implemented YF preventive vaccination campaigns. ► 38 million people were vaccinated against YF and 164 serious adverse events observed. ► Few serious adverse events results from YF vaccine. ► Our results reinforce the generally accepted safety profile of YF vaccine. ► The continued use of YF vaccine during preventive vaccination campaigns is supported.